Skip to content
Question
Can I get it prescribed?
What it costs
$199/mo
Read
8 min
Published
September 2026

PT-141 Peptide for Men: The Label Excludes Them, and the Market Prices It Anyway

The approved bremelanotide product states in its Limitations of Use that it is not indicated in men, and its phase 3 program enrolled 1,247 premenopausal women. What the compounded route costs a month, and what the two published male studies actually tested.

ByJenna PrattConsumer-access reporterPublished

A man buying PT-141 in the United States is buying a compounded product, and a typical month across sellers that publish a figure runs $199. The approved product is not an option for him, and the reason is printed on the label rather than hidden in a policy somewhere.

Compounded PT-141, per month, by route, September 2026
InjectionNasal spray
Sellers publishing a month339
Lowest published month$73$151
Typical (median) month$199$199
Highest published month$328$249
Compounded PT-141, per month, by route, September 2026. Computed from every tracked seller that publishes a monthly figure for that route, each counted once at its lowest month. A month here is what the seller bills, not a count of doses.

The spread inside the injection column is wider than the gap between the two routes, which is the practical point for anyone comparing quotes. The dose-by-dose arithmetic sits in PT 141 cost, and the nasal form is priced on its own in PT 141 nasal spray.

What the approved label says about men

Vyleesi is indicated for premenopausal women with acquired, generalized hypoactive sexual desire disorder, and its Limitations of Use are explicit: it is not indicated for the treatment of that condition in postmenopausal women or in men[1].

A second limitation sits directly beneath it. The product is not indicated to enhance sexual performance[1].

The evidence behind the approval matches the indication. Efficacy and safety were studied in two identical 24-week randomized, double-blind, placebo-controlled trials in 1,247 premenopausal women, aged 19 to 56, with a mean age of 39[1].

FDA approved the application on June 21, 2019[2]. Nothing in that record covers a male indication, and no approved bremelanotide product for men has followed.

Why a compounded version is available at all

Because bremelanotide is a component of an approved drug, federal law permits a pharmacy to compound from it, subject to the statute's other conditions[3].

That is a rule about the substance, not about who it is for. A compounded product is not an approved product, so nothing about the label's exclusion of men is overridden by a pharmacy making it; the prescription is simply written outside the approved indication.

What the prescriber and the pharmacy each have to be, and where a telehealth visit fits, is covered in PT 141 prescription and who can prescribe peptides.

The two published studies that did enroll men

Both were run by the compound's developer, and both used an intranasal spray rather than the subcutaneous autoinjector that was eventually approved.

The first was a double-blind, placebo-controlled evaluation in healthy males and in patients with mild-to-moderate erectile dysfunction who responded to sildenafil[4]. Erectile response was statistically significant against placebo at doses above 7 mg, with the first erection at roughly 30 minutes[4].

Its pharmacokinetics are worth noting beside a monthly price, because they describe a short-acting product: median time to peak concentration was 0.50 hours and mean half-life ran from 1.85 to 2.09 hours[4]. Flushing and nausea were the most common adverse events[4].

The second study gave 19 men with erectile dysfunction three combinations in a randomized crossover design[5]. Those were 25 mg sildenafil with 7.5 mg intranasal PT-141, 25 mg sildenafil with a placebo spray, and a placebo tablet with a placebo spray[5].

The erectile response from the combination was significantly greater than sildenafil alone, and the authors concluded that co-administration may be an alternative where higher doses of one therapy are not effective or tolerated[5].

Nineteen men, one crossover session each, a nasal spray at a dose the approved injector does not have: that is the size of the male evidence base, and it is a sponsor's own dataset.

How to read a monthly quote for it

The approved label recommends no more than eight doses a month, and notes that few patients in the phase 3 program received more than that[1]. A seller's “month” may contain far fewer doses than eight, or may not state a dose count at all.

  • How many doses does the monthly price buy, and at what strength?
  • Is the price a subscription, and what does month two cost?
  • Is a consult or membership fee billed on top, and how is it canceled?

Those fees are where most of the money moves, and they are set out in peptide therapy cost. Cancellation terms are in how to cancel a peptide subscription.

FAQ

5 questions

Is PT-141 approved for men in the United States?

No. The approved bremelanotide product is indicated for premenopausal women with acquired, generalized hypoactive sexual desire disorder, and its Limitations of Use state that it is not indicated in postmenopausal women or in men, and not indicated to enhance sexual performance.

How much does PT-141 cost for a man?

The route open to a man is a compounded one, and its monthly market is computed here from every tracked seller that publishes a monthly figure, each counted once at its lowest month. The spread between the cheapest and the most costly month is wider than the gap between the injection and the nasal spray.

What research has tested PT-141 in men?

Two published studies from the compound's developer. One was a double-blind placebo-controlled evaluation of an intranasal spray in healthy males and men with mild-to-moderate erectile dysfunction, and the other gave 19 men 7.5 mg intranasal PT-141 with 25 mg sildenafil in a crossover design. Both used a nasal route the approved product does not have.

Does PT-141 raise blood pressure?

The approved label records maximal increases of 6 mmHg systolic and 3 mmHg diastolic peaking two to four hours after a dose, with heart rate falling up to 5 beats per minute and both usually back to baseline within twelve hours. It is contraindicated in uncontrolled hypertension or known cardiovascular disease.

How many doses should a monthly price cover?

The approved label recommends no more than eight doses a month and notes that few patients in the phase 3 program received more than that. A seller's monthly figure may buy far fewer doses, so the dose count is the first thing to ask for when comparing two quotes.

Sources

5 cited
  1. [1]Cosette Pharmaceuticals, Inc. (2024). VYLEESI (bremelanotide) injection, for subcutaneous use: Prescribing Information DailyMed, U.S. National Library of Medicine. Source
  2. [2]Food and Drug Administration (2019). NDA 210557 approval letter, VYLEESI (bremelanotide) injection Drugs@FDA. Source
  3. [3]United States Code (2024). 21 U.S.C. 353a, Pharmacy compounding Office of the Law Revision Counsel. Source
  4. [4]Diamond LE, Earle DC, Rosen RC, Willett MS, Molinoff PB (2004). Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction International Journal of Impotence Research. PMID 14963471
  5. [5]Diamond LE, Earle DC, Garcia WD, Spana C (2005). Co-administration of low doses of intranasal PT-141, a melanocortin receptor agonist, and sildenafil to men with erectile dysfunction results in an enhanced erectile response Urology. PMID 15833522

Where to buy PT-141 (bremelanotide)

Lowest injection prices
  1. 1ImmortalsOur review$73/moGet price →
  2. 2Nu Image MedicalOur review$84/moGet price →
  3. 3EOS HealthOur review$135.20/moGet price →

Medication price as each seller publishes it, before fees. The full PT-141 (bremelanotide) price board